Achilles Therapeutics (ACHL) shares were up 1.1% Tuesday morning after the company said it sold certain technology assets to AstraZeneca (AZN) for $12 million.
The company said it transferred a commercial license of proprietary data and samples from the TRACERx non-small cell lung cancer study to AstraZeneca.
Achilles said the sale concludes a strategic review it had first announced in September. The company said it now plans to further reduce its employee headcount and decrease the size of its board.
Price: 0.99, Change: +0.01, Percent Change: +1.11
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。